SCHEMBL215105

SCHEMBL215105

CN(C)CCN1CCc2c[c]ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
MAPT P10636 4/20 0.63
KDM4E B2RXH2 4/20 0.63
LMNA P02545 3/20 0.63
PTK2B Q14289 1/20 0.63
ESR2 Q92731 1/20 0.63
NOS3 P29474 5/20 0.41
NOS1 P29475 5/20 0.41
NOS2 P35228 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
USP2 O75604 1/20 0.41
CDK4 P11802 1/20 0.41
ALOX15 P16050 1/20 0.41
CCND1 P24385 1/20 0.41
SLC6A4 P31645 2/20 0.35
HRH1 P35367 2/20 0.35
HTR3E A5X5Y0 1/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450394 0.88 ALDH1A1 (0.63) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL1451152 0.79 ALDH1A1 (0.52) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL4813901 0.79 ALDH1A1 (0.39) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL7680979 0.78 ALDH1A1 (1.00) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL216145 0.75 NOS3 (0.44) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL28598636 0.75 ALDH1A1 (0.40) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL25818505 0.74 ALDH1A1 (0.65) ALDH1A1MAPTKDM4ELMNAPTK2B
SCHEMBL2090062 0.74 MEN1 (0.60) ALDH1A1MAPTKDM4ELMNAMEN1
SCHEMBL1419127 0.73 MAPT (0.34) ALDH1A1MAPTMEN1KMT2AUSP2
SCHEMBL14016156 0.73 MAPT (0.63) ALDH1A1MAPTKDM4ELMNAPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168966-B1 BICYCLOANILINE DERIVATIVE MSD KK (JP) 2016-09-28 EP disclosed
US-8436004-B2 Bicycloaniline derivative MSD K.K. (JP) 2013-05-07 US disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
US-20110135601-A1 BICYCLOANILINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2011-06-09 US disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135601-A1 BICYCLOANILINE DERIVATIVE WEE1, WEE2, CCNK ALDH1A1 1894/4885MAPT 4695/4885KDM4E 1635/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK ALDH1A1 1119/4885MAPT 4723/4885KDM4E 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.